Electrolyte disorders related to EGFR-targeting drugs.
It is now clearly established that anti-vascular endothelial growth factor (VEGF) drug class induces hypertension and proteinuria sometimes related to thrombotic microangiopathy and/or various glomerulopathies, according to capillary and glomerular VEGF and VEGF-receptor expressions. As reported in the literature, anti-epidermal growth factor receptor (EGFR) therapies seem to be less nephrotoxic. Indeed, many reports of anti-EGFR nephrotoxicity are tubular dependent such as acute tubular necrosis, electrolyte disorders (hypophosphatemia, hypomagnesemia, etc.) or both. This is explained by elective tubular expression of renal EGF/EGFR. In this paper, we focus on electrolyte disorders related to anti-EGFR treatment and discuss the tubular involvement of these drugs based on their renal expression.
Izzedine
Hassane
H
Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France. hassan.izzedine@psl.ap-hop-paris.fr
Bahleda
Rastilav
R
Khayat
David
D
Massard
Christophe
C
Magné
Nicolas
N
Spano
Jean Philippe
JP
Soria
Jean Charles
JC
D000818:Animals; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced* / Q000503:physiopathology
D066246:ErbB Receptors